Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25104627 | 0.78 | CYP1A2 (0.39) | ADORA2AADORA1ADORA3ADORA2BKDM4E | |
| SCHEMBL18359326 | 0.77 | ADORA3 (0.39) | ADORA2AADORA1ADORA3ADORA2BTP53 | |
| SCHEMBL20023744 | 0.76 | ADORA2A (0.41) | ADORA2AADORA1ADORA3 | |
| SCHEMBL30952516 | 0.72 | ADORA2A (0.36) | ADORA2AADORA1SMN1; SMN2 | |
| SCHEMBL12725087 | 0.72 | PDE4A (0.35) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL19281108 | 0.71 | LRRK2 (0.34) | — | |
| SCHEMBL20023757 | 0.69 | ADORA1 (0.51) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL24166154 | 0.69 | KDM4E (0.38) | ADORA2AADORA1ADORA3ADORA2BKDM4E | |
| SCHEMBL10506807 | 0.69 | LMNA (0.41) | ADORA2AADORA1ADORA3ADORA2BKDM4E | |
| SCHEMBL22118906 | 0.68 | PDE4B (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4594305-A1 | TEAD INHIBITORS AND METHODS OF USES THEREOF | Insilico Medicine IP Limited (HK) | 2025-08-06 | — | — | EP | disclosed |
| CN-120020133-A | Nitrogen-containing heterocyclic derivative and medical application thereof | 杭州百新生物医药科技有限公司 | 2025-05-20 | — | — | CN | disclosed |
| CN-119968359-A | TEAD inhibitors and methods of use thereof | 英矽智能科技知识产权有限公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2024233605-A1 | COMPOUNDS AND THEIR USE AGAINST CANCER | TANGO THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-12103915-B2 | TEAD inhibitors and methods of uses thereof | INSILICO MEDICINE IP LIMITED (HK) | 2024-10-01 | — | — | US | disclosed |
| US-20240166608-A1 | TEAD INHIBITORS AND METHODS OF USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2024-05-23 | — | — | US | disclosed |
| WO-2024067773-A1 | TEAD INHIBITORS AND METHODS OF USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-04-04 | — | — | WO | disclosed |
| US-20230406860-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. | 2023-12-21 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| EP-4217348-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BeiGene, Ltd. (KY) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023034812-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2022063106-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEIGENE, LTD. (KY) | 2022-03-31 | — | — | WO | disclosed |
| US-10822342-B2 | Pyrazolopyrimidine derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-03 | — | — | US | disclosed |
| US-20190169198-A1 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-06 | — | — | US | disclosed |
| US-10221180-B2 | Pyrazolopyrimidine derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-05 | — | — | US | disclosed |
| EP-3209663-B1 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-12-12 | — | — | EP | disclosed |
| US-20170334915-A1 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
| EP-3209663-A1 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES AS NIK INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2017-08-30 | — | — | EP | disclosed |
| WO-2017004133-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| WO-2013051632-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2013-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406860-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | ADORA2A 4202/4885ADORA1 4527/4885ADORA3 4630/4885 |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | ADORA2A 1376/4885ADORA1 2095/4885ADORA3 1865/4885 |
| US-12103915-B2 | TEAD inhibitors and methods of uses thereof | TEAD2, TEAD3, TEAD4 | ADORA2A 3121/4885ADORA1 4304/4885ADORA3 4084/4885 |
| US-20190169198-A1 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES AS NIK INHIBITORS | MAP3K14, MAP3K15, MAP3K19 | ADORA2A 4712/4885ADORA1 4687/4885ADORA3 4644/4885 |
| US-20240166608-A1 | TEAD INHIBITORS AND METHODS OF USES THEREOF | TEAD2, TEAD3, TEAD4 | ADORA2A 3121/4885ADORA1 4304/4885ADORA3 4084/4885 |
| US-20170334915-A1 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES AS NIK INHIBITORS | MAP3K14, MAP3K15, MAP3K19 | ADORA2A 4712/4885ADORA1 4687/4885ADORA3 4644/4885 |
| US-10822342-B2 | Pyrazolopyrimidine derivatives as NIK inhibitors | MAP3K14, MAP3K15, MAP3K12 | ADORA2A 4767/4885ADORA1 4744/4885ADORA3 4619/4885 |
| US-10221180-B2 | Pyrazolopyrimidine derivatives as NIK inhibitors | MAP3K14, MAP3K15, MAP3K12 | ADORA2A 4767/4885ADORA1 4744/4885ADORA3 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.